Skip to main content
SpringerLink
Log in

Merck announces worldwide suspension of Tredaptive

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Merck. Merck Provides Update on Next Steps for TREDAPTIVE (extendedrelease niacin/laropiprant). Media Release : 11 Jan 2013. Available from: URL: http://www.merck.com.

  2. EMA. PRAC considers that benefit-risk balance of Tredaptive, Pelzont and Trevaclyn (nicotinic acid/laropiprant) is negative. Internet Document : [3 pages], 10 Jan 2013. Available from: URL: http://www.ema.europa.eu.

Download references

Additional information

* see Reactions 1434 p4; 801161396

Rights and permissions

Reprints and permissions

About this article

Cite this article

Merck announces worldwide suspension of Tredaptive. Reactions Weekly 1436, 1 (2013). https://doi.org/10.1007/s40278-013-0853-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-013-0853-7

Search

Navigation